B-condition	0	4	Pain
I-condition	5	8	and
I-condition	9	15	health
I-condition	15	16	-
I-condition	16	23	related
I-condition	24	31	quality
I-condition	32	34	of
I-condition	35	39	life
O	40	42	in
O	43	51	patients
O	52	56	with
O	57	65	advanced
O	66	71	solid
O	72	79	tumours
O	80	83	and
O	84	88	bone
O	89	99	metastases
O	99	100	:
O	101	111	integrated
O	112	119	results
O	120	124	from
O	125	130	three
O	131	141	randomized
O	141	142	,
O	143	149	double
O	149	150	-
O	150	155	blind
O	156	163	studies
O	164	166	of
B-intervention	167	176	denosumab
O	177	180	and
B-control	181	191	zoledronic
I-control	192	196	acid
O	196	197	.

O	198	202	This
O	203	211	analysis
O	212	221	evaluated
O	222	229	patient
O	229	230	-
O	230	238	reported
O	239	247	outcomes
O	248	251	and
O	252	261	analgesic
O	262	265	use
O	266	268	in
O	269	277	patients
O	278	282	with
O	283	287	bone
O	288	298	metastases
O	299	303	from
O	304	309	solid
O	310	317	tumours
O	318	324	across
O	325	330	three
O	331	342	comparative
O	343	350	studies
O	351	353	of
O	354	363	denosumab
O	364	367	and
O	368	378	zoledronic
O	379	383	acid
O	383	384	.

O	385	391	Pooled
O	392	396	data
O	397	401	were
O	402	410	analysed
O	411	415	from
O	416	421	three
O	422	433	identically
O	434	442	designed
O	443	449	double
O	449	450	-
O	450	455	blind
O	456	461	phase
O	462	465	III
O	466	473	studies
O	474	483	comparing
O	484	496	subcutaneous
O	497	506	denosumab
O	507	510	120
O	511	513	mg
O	514	518	with
O	519	530	intravenous
O	531	541	zoledronic
O	542	546	acid
O	547	548	4
O	549	551	mg
O	552	559	monthly
O	560	562	in
B-eligibility	563	571	patients
I-eligibility	572	576	with
I-eligibility	577	581	bone
I-eligibility	582	592	metastases
I-eligibility	593	597	from
I-eligibility	598	604	breast
I-eligibility	605	611	cancer
O	612	613	(
O	613	614	n
O	615	616	=
B-total-participants	617	618	2
I-total-participants	618	619	,
I-total-participants	619	622	046
O	622	623	)
O	623	624	,
O	625	635	castration
O	635	636	-
O	636	645	resistant
O	646	654	prostate
O	655	661	cancer
O	662	663	(
O	663	664	n
O	665	666	=
B-total-participants	667	668	1
I-total-participants	668	669	,
I-total-participants	669	672	901
O	672	673	)
O	674	676	or
O	677	682	other
O	683	688	solid
O	689	696	tumours
O	697	698	(
O	698	699	n
O	700	701	=
B-total-participants	702	703	1
I-total-participants	703	704	,
I-total-participants	704	707	597
O	707	708	)
O	708	709	.

O	710	714	Pain
O	715	723	severity
O	723	724	,
O	725	729	pain
O	730	742	interference
O	742	743	,
O	744	750	health
O	750	751	-
O	751	758	related
O	759	766	quality
O	767	769	of
O	770	774	life
O	775	778	and
O	779	788	analgesic
O	789	792	use
O	793	797	were
O	798	808	quantified
O	808	809	.

O	810	812	At
O	813	821	baseline
O	821	822	,
O	823	836	approximately
O	837	841	half
O	842	844	of
O	845	853	patients
O	854	857	had
B-outcome	858	860	no
I-outcome	860	861	/
I-outcome	861	865	mild
I-outcome	866	870	pain
O	871	872	(
B-iv-bin-percent	872	874	53
I-iv-bin-percent	875	876	%
O	877	878	[
B-iv-bin-abs	878	879	1
I-iv-bin-abs	879	880	,
I-iv-bin-abs	880	883	386
O	883	884	/
B-intervention-participants	884	885	2
I-intervention-participants	885	886	,
I-intervention-participants	886	889	620
O	889	890	]
O	891	900	denosumab
O	900	901	;
B-cv-bin-percent	902	904	50
I-cv-bin-percent	905	906	%
O	907	908	[
B-cv-bin-abs	908	909	1
I-cv-bin-abs	909	910	,
I-cv-bin-abs	910	913	297
O	913	914	/
B-control-participants	914	915	2
I-control-participants	915	916	,
I-control-participants	916	919	578
O	919	920	]
O	921	931	zoledronic
O	932	936	acid
O	936	937	)
O	937	938	.

O	939	948	Denosumab
O	949	956	delayed
B-outcome	957	962	onset
I-outcome	963	965	of
I-outcome	966	974	moderate
I-outcome	974	975	/
I-outcome	975	981	severe
I-outcome	982	986	pain
O	987	989	by
O	990	991	1
O	991	992	.
O	992	993	8
O	994	1000	months
O	1001	1002	(
O	1002	1008	median
O	1008	1009	,
B-iv-cont-median	1010	1011	6
I-iv-cont-median	1011	1012	.
I-iv-cont-median	1012	1013	5
O	1014	1016	vs
B-cv-cont-median	1017	1018	4
I-cv-cont-median	1018	1019	.
I-cv-cont-median	1019	1020	7
I-cv-cont-median	1021	1027	months
O	1027	1028	;
O	1029	1035	hazard
O	1036	1041	ratio
O	1041	1042	,
O	1043	1044	0
O	1044	1045	.
O	1045	1047	83
O	1047	1048	;
O	1049	1051	95
O	1052	1053	%
O	1054	1056	CI
O	1056	1057	,
O	1058	1059	0
O	1059	1060	.
O	1060	1062	76
O	1062	1063	-
O	1063	1064	0
O	1064	1065	.
O	1065	1067	92
O	1067	1068	;
O	1069	1070	p
O	1071	1072	<
O	1073	1074	0
O	1074	1075	.
O	1075	1078	001
O	1078	1079	;
O	1080	1082	17
O	1083	1084	%
O	1085	1089	risk
O	1090	1099	reduction
O	1099	1100	)
O	1101	1104	and
O	1105	1115	clinically
O	1116	1126	meaningful
O	1127	1136	increases
O	1137	1139	in
B-outcome	1140	1147	overall
I-outcome	1148	1152	pain
I-outcome	1153	1165	interference
O	1166	1168	by
O	1169	1170	2
O	1170	1171	.
O	1171	1172	6
O	1173	1179	months
O	1180	1181	(
O	1181	1187	median
O	1187	1188	,
B-iv-cont-median	1189	1191	10
I-iv-cont-median	1191	1192	.
I-iv-cont-median	1192	1193	3
O	1194	1196	vs
B-cv-cont-median	1197	1198	7
I-cv-cont-median	1198	1199	.
I-cv-cont-median	1199	1200	7
I-cv-cont-median	1201	1207	months
O	1207	1208	;
O	1209	1215	hazard
O	1216	1221	ratio
O	1221	1222	,
O	1223	1224	0
O	1224	1225	.
O	1225	1227	83
O	1227	1228	;
O	1229	1231	95
O	1232	1233	%
O	1234	1236	CI
O	1236	1237	,
O	1238	1239	0
O	1239	1240	.
O	1240	1242	75
O	1242	1243	-
O	1243	1244	0
O	1244	1245	.
O	1245	1247	92
O	1247	1248	;
O	1249	1250	p
O	1251	1252	<
O	1253	1254	0
O	1254	1255	.
O	1255	1258	001
O	1258	1259	;
O	1260	1262	17
O	1263	1264	%
O	1265	1269	risk
O	1270	1279	reduction
O	1279	1280	)
O	1281	1289	compared
O	1290	1294	with
O	1295	1305	zoledronic
O	1306	1310	acid
O	1310	1311	.

O	1312	1318	Strong
O	1319	1325	opioid
O	1326	1329	use
O	1330	1333	and
O	1334	1343	worsening
O	1344	1346	of
B-outcome	1347	1353	health
I-outcome	1353	1354	-
I-outcome	1354	1361	related
I-outcome	1362	1369	quality
I-outcome	1370	1372	of
I-outcome	1373	1377	life
O	1378	1382	were
O	1383	1387	less
O	1388	1394	common
O	1395	1399	with
O	1400	1409	denosumab
O	1409	1410	.

O	1411	1417	Across
O	1418	1423	three
O	1424	1429	large
O	1430	1437	studies
O	1438	1440	of
O	1441	1449	patients
O	1450	1454	with
O	1455	1463	advanced
O	1464	1469	solid
O	1470	1477	tumours
O	1478	1481	and
O	1482	1486	bone
O	1487	1497	metastases
O	1497	1498	,
O	1499	1508	denosumab
O	1509	1518	prevented
O	1519	1530	progression
O	1531	1533	of
O	1534	1538	pain
O	1539	1547	severity
O	1548	1551	and
O	1552	1556	pain
O	1557	1569	interference
O	1570	1574	more
O	1575	1586	effectively
O	1587	1591	than
O	1592	1602	zoledronic
O	1603	1607	acid
O	1607	1608	.
